Bremelanotide, Vyleesi · Evidence-based safety and harm-reduction overview.
| Also known as | Bremelanotide, Vyleesi |
| Category | Peptide |
| fda_approval | Vyleesi approved June 2019 for acquired generalized HSDD in premenopausal women |
| mechanism_class | Melanocortin receptor agonist (melanotropic peptide) |
| route | Subcutaneous injection |
| onset | approximately 15-30 minutes; effects last a few hours |
| US legal status | Bremelanotide is the active ingredient in Vyleesi, an FDA-approved prescription product for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Raw 'PT-141' sold by research-chemical vendors is not FDA-approved, is not legal to sell for human consumption, and is typically labeled 'for research use only.' Possession or use outside a prescription falls into a legal gray area and unapproved supply is unregulated. |
PT-141 is a synthetic melanocortin receptor agonist, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH). Unlike phosphodiesterase-5 (PDE5) inhibitors that act primarily on blood-vessel smooth muscle, PT-141 acts on melanocortin receptors in the central nervous system thought to influence sexual desire and arousal pathways.
PT-141 crosses the blood-brain barrier and binds melanocortin receptors (particularly MC1R and MC4R) in hypothalamic and limbic regions involved in arousal and sexual motivation. This receptor activation is thought to increase dopaminergic and noradrenergic signaling in neural circuits mediating desire, distinct from vasodilatory or phosphodiesterase-related mechanisms.
PT-141 was developed as a potential melanoma-treating agent in the 1980s when researchers noticed sexual side effects. Its development was redirected toward sexual dysfunction, and clinical trials for HSDD began in the 2010s, leading to FDA approval of bremelanotide (Vyleesi) in 2019 for premenopausal women with acquired HSDD.
Research suggests bremelanotide can modestly increase self-reported sexual desire and reduce distress in women with HSDD, which formed the basis of its FDA approval as Vyleesi in 2019. Studies report melanocortin-mediated effects on arousal circuits, though effect sizes in clinical trials were modest and some endpoints did not fully separate from placebo. Human evidence for off-label use in men or for recreational purposes is substantially lower in quality than the controlled HSDD regulatory data.
In clinical trials, bremelanotide was administered as a subcutaneous injection 45 minutes before anticipated sexual activity, with studied doses ranging from 0.75 to 2 mg per dose, and protocols limiting frequency to no more than once per 24 hours.
This is general research/context information, not medical advice or a recommended protocol.
Combining PT-141 with phosphodiesterase-5 inhibitors (like sildenafil) in gray-market contexts is unstudied and creates compounded cardiovascular risk; the combination is not recommended outside clinical supervision.
If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.
Compare testing optionsNo. Viagra (sildenafil) is a phosphodiesterase-5 inhibitor that acts on blood flow and vascular smooth muscle, while PT-141 (bremelanotide) is a melanocortin receptor agonist acting on central nervous system arousal circuits. They work by entirely different mechanisms.
We do not provide dosing guidance for self-injection of an unapproved research compound. If you have a clinical reason to consider bremelanotide, the only appropriate path is a prescription and supervision from a licensed clinician.
Yes. Studies and the approved-product labeling note transient increases in blood pressure and decreases in heart rate, which is why it is not advised for people with cardiovascular disease or uncontrolled hypertension.
Melanocortin activation can cause reversible or persistent hyperpigmentation, particularly in darker-skinned individuals and with repeated dosing. This is a recognized risk of melanocortin agonists.
Research on drug interactions is limited. Any use alongside serotonergic, stimulant, or cardiovascular medications should be discussed with a clinician; self-combining is unsafe.
Medical & legal disclaimer. This site is for informational and harm-reduction purposes only. It is not medical advice and is not a substitute for a licensed healthcare professional. The compounds discussed are largely not approved by the FDA for human use and many are sold strictly as research chemicals 'not for human consumption.' Nothing here is an endorsement to purchase, possess, or use any substance. Laws vary by jurisdiction. Always consult a qualified physician and follow the law where you live.
Some links on this page may be affiliate links. If you buy through them we may earn a commission at no extra cost to you. This never changes the safety information we publish.